160 related articles for article (PubMed ID: 28949997)
1. Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease.
Olivera MJ; Cucunubá ZM; Valencia-Hernández CA; Herazo R; Agreda-Rudenko D; Flórez C; Duque S; Nicholls RS
PLoS One; 2017; 12(9):e0185033. PubMed ID: 28949997
[TBL] [Abstract][Full Text] [Related]
2. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.
Sperandio da Silva GM; Mediano MF; Alvarenga Americano do Brasil PE; da Costa Chambela M; da Silva JA; de Sousa AS; Xavier SS; Rodrigues da Costa A; Magalhães Saraiva R; Hasslocher-Moreno AM
Antimicrob Agents Chemother; 2014 Nov; 58(11):6371-7. PubMed ID: 25114135
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults.
Olivera MJ; Cucunubá ZM; Álvarez CA; Nicholls RS
Am J Trop Med Hyg; 2015 Dec; 93(6):1224-1230. PubMed ID: 26392162
[TBL] [Abstract][Full Text] [Related]
4. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.
Sperandio da Silva GM; Mediano MFF; Hasslocher-Moreno AM; Holanda MT; Silvestre de Sousa A; Sangenis LHC; Brasil PEAAD; Mejía RA; Fux CP; Cubides JC; Saraiva RM; Brum-Soares LM
J Antimicrob Chemother; 2017 Sep; 72(9):2596-2601. PubMed ID: 28645201
[TBL] [Abstract][Full Text] [Related]
5. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole.
Franco LAM; Moreira CHV; Buss LF; Oliveira LC; Martins RCR; Manuli ER; Lindoso JAL; Busch MP; Pereira AC; Sabino EC
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669428
[TBL] [Abstract][Full Text] [Related]
7. Safety of benznidazole use in the treatment of chronic Chagas' disease.
Hasslocher-Moreno AM; do Brasil PE; de Sousa AS; Xavier SS; Chambela MC; Sperandio da Silva GM
J Antimicrob Chemother; 2012 May; 67(5):1261-6. PubMed ID: 22331592
[TBL] [Abstract][Full Text] [Related]
8. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease.
Kratz JM; Garcia Bournissen F; Forsyth CJ; Sosa-Estani S
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):943-957. PubMed ID: 30111183
[TBL] [Abstract][Full Text] [Related]
10. Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis.
Ciapponi A; Barreira F; Perelli L; Bardach A; Gascón J; Molina I; Morillo C; Prado N; Riarte A; Torrico F; Ribeiro I; Villar JC; Sosa-Estani S
PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008529. PubMed ID: 32804966
[TBL] [Abstract][Full Text] [Related]
11. Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil.
Gontijo MKCL; Arruda HMBDS; Noronha EF; Toledo MI
Rev Soc Bras Med Trop; 2020; 53():e20190150. PubMed ID: 31994658
[TBL] [Abstract][Full Text] [Related]
12. Clomipramine and benznidazole association for the treatment of acute experimental Trypanosoma cruzi infection.
Strauss M; Lo Presti MS; Bazán PC; Baez A; Fauro R; Esteves B; Sanchez Negrete O; Cremonezzi D; Paglini-Oliva PA; Rivarola HW
Parasitol Int; 2013 Jun; 62(3):293-9. PubMed ID: 23500720
[TBL] [Abstract][Full Text] [Related]
13. Tolerance of benznidazole in a United States Chagas Disease clinic.
Miller DA; Hernandez S; Rodriguez De Armas L; Eells SJ; Traina MM; Miller LG; Meymandi SK
Clin Infect Dis; 2015 Apr; 60(8):1237-40. PubMed ID: 25601454
[TBL] [Abstract][Full Text] [Related]
14. Impact of the Use of Benznidazole Followed by Antioxidant Supplementation in the Prevalence of Ventricular Arrhythmias in Patients With Chronic Chagas Disease: Pilot Study.
Barbosa JL; Thiers CA; de Bragança Pereira B; do Nascimento EM; Ribeiro Frazon CM; Budni P; Wilhelm Filho D; Pedrosa RC
Am J Ther; 2016; 23(6):e1474-e1483. PubMed ID: 25461962
[TBL] [Abstract][Full Text] [Related]
15. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.
Pinazo MJ; Guerrero L; Posada E; Rodríguez E; Soy D; Gascon J
Antimicrob Agents Chemother; 2013 Jan; 57(1):390-5. PubMed ID: 23114763
[TBL] [Abstract][Full Text] [Related]
16. Response to different benznidazole doses in animal models of chronic phase Chagas disease: a critical review.
Scarim CB; Ribeiro AR; Rosa JAD; Chin CM
Rev Soc Bras Med Trop; 2018; 51(2):133-140. PubMed ID: 29768544
[TBL] [Abstract][Full Text] [Related]
17. Adverse events after the use of benznidazole in infants and children with Chagas disease.
Altcheh J; Moscatelli G; Moroni S; Garcia-Bournissen F; Freilij H
Pediatrics; 2011 Jan; 127(1):e212-8. PubMed ID: 21173000
[TBL] [Abstract][Full Text] [Related]
18. Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil.
Ferreira AM; Sabino EC; de Oliveira LC; Oliveira CD; Cardoso CS; Ribeiro AL; Haikal DS
PLoS One; 2016; 11(11):e0165950. PubMed ID: 27855177
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease.
Salvador F; Sánchez-Montalvá A; Martínez-Gallo M; Sala-Cunill A; Viñas L; García-Prat M; Aparicio G; Sao Avilés A; Artaza MÁ; Ferrer B; Molina I
Clin Infect Dis; 2015 Dec; 61(11):1688-94. PubMed ID: 26265500
[TBL] [Abstract][Full Text] [Related]
20. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients.
Álvarez MG; Hernández Y; Bertocchi G; Fernández M; Lococo B; Ramírez JC; Cura C; Albizu CL; Schijman A; Abril M; Sosa-Estani S; Viotti R
Antimicrob Agents Chemother; 2016 Feb; 60(2):833-7. PubMed ID: 26596935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
